oxonic acid has been researched along with Cancer of Esophagus in 102 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 9.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable." | 7.85 | A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. ( Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP, 2017) |
| "The combination chemotherapy using S-1 and irinotecan showed tolerable clinical efficacy in terms of the response rate, survival and toxicity for esophageal adenocarcinoma." | 7.78 | A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma. ( Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y, 2012) |
| "Background Esophageal cancer is a very common malignant tumor in China, especially esophageal squamous cell carcinoma (ESCC), but there is currently no effective treatment for patients after first-line chemotherapy failure." | 6.94 | Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. ( Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | 6.82 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| "4%) and renal adverse events (all grades: CS, 18." | 6.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "She had received 4 cycles of palliative therapy using oral apatinib (425 mg daily) plus S-1 (40 mg twice daily for 4 weeks, with a 2-week drug-free interval), followed by maintenance low-dose apatinib (250 mg daily) plus S-1 at the same dosage thereafter." | 6.66 | S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. ( Liu, D; Yu, GM; Zhang, C; Zhang, M, 2020) |
| " Patients were treated with apatinib combined with S-1 /capecitabine after dCRT." | 5.62 | Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. ( Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y, 2021) |
| "In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC)." | 5.34 | An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. ( Hattori, N; Hayashi, M; Iwata, N; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Omae, K; Shimizu, D; Tanaka, C; Yamada, S, 2020) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 5.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile." | 5.14 | Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010) |
| "Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)." | 3.91 | S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019) |
| "In advanced esophageal squamous cell carcinoma (ESCC), paclitaxel plus cisplatin are considered as active and tolerable." | 3.85 | A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. ( Jin, SL; Liu, YY; Luo, SX; Tang, H; Wang, HY; Yang, SJ; Yao, SN; Yao, ZH; Zhao, Y; Zhou, WP, 2017) |
| "The combination chemotherapy using S-1 and irinotecan showed tolerable clinical efficacy in terms of the response rate, survival and toxicity for esophageal adenocarcinoma." | 3.78 | A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma. ( Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y, 2012) |
| "We treated a patient with inoperable advanced gastric cancer and malignant ascites by combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)." | 3.72 | [A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)]. ( Funai, S; Hirai, T; Kamei, A; Ohtsuka, H; Shindo, K; Shiozaki, H; Tanaka, A; Yoshifuji, T, 2003) |
| "Background Esophageal cancer is a very common malignant tumor in China, especially esophageal squamous cell carcinoma (ESCC), but there is currently no effective treatment for patients after first-line chemotherapy failure." | 2.94 | Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. ( Lei, J; Song, X; Wang, Y; Yu, J; Zhang, C; Zhang, N; Zhang, S; Zhao, J, 2020) |
| "The KEYNOTE-659 study evaluated the efficacy and safety of pembrolizumab in combination with chemotherapy as the first-line treatment in Japanese patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer." | 2.94 | Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. ( Amagai, K; Azuma, M; Baba, H; Esaki, T; Han, SR; Hara, H; Hosaka, H; Kawakami, H; Kawazoe, A; Komatsu, Y; Machida, N; Negoro, Y; Nishina, T; Omuro, Y; Oshima, T; Shiratori, S; Shitara, K; Tsuda, M; Yamaguchi, K; Yasui, H; Yoshida, K, 2020) |
| "Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy." | 2.90 | Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. ( Cai, H; Du, C; Fang, Y; Huang, D; Huang, H; Jin, J; Li, G; Liu, X; Long, Z; Lu, Q; Ma, M; Sheng, W; Wang, Y; Wu, J; Xie, L; Yin, J; Zhang, Z; Zhao, G; Zhou, M; Zhou, Y; Zhu, H; Zhu, J; Zhu, X, 2019) |
| "The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established." | 2.90 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. ( Ba, Y; Bai, Y; Cheng, Y; Fan, Q; Feng, J; Hu, C; Huang, J; Li, J; Liu, Y; Lu, P; Ma, C; Wang, X; Wen, L; Wu, L; Xu, B; Yuan, X; Zhang, S, 2019) |
| "The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study." | 2.90 | A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019) |
| "Although standard chemotherapy for esophageal cancer patients is fluorouracil and cisplatin, the prognosis is still unsatisfactory." | 2.82 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. ( Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K, 2016) |
| "Patients with stage II, III, or IVA esophageal cancer were randomly allocated to either 2 cycles of ICT (oxaliplatin 130 mg/m(2) on day 1 and S1 at 40 mg/m(2) twice daily on days 1-14, every 3 weeks) followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m(2) on days 1 and 21 and S1 30 mg/m(2) twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A), or the same CCRT followed by esophagectomy without ICT (arm B)." | 2.80 | Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer. ( Cho, KJ; Jang, G; Jung, HY; Kim, HR; Kim, JH; Kim, JY; Kim, SB; Kim, YH; Lee, GH; Ryu, JS; Song, HY; Yoon, DH, 2015) |
| "Thoracic esophageal cancer patients with clinical stage II/III disease, excluding T4, were eligible." | 2.80 | Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604). ( Boku, N; Fuse, N; Kanato, K; Kato, K; Mizusawa, J; Muro, K; Nihei, K; Ohtsu, A; Sato, A; Tahara, M; Takaishi, H; Yamazaki, K, 2015) |
| "Eligible patients had stage IIA-IVA esophageal cancer." | 2.79 | A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. ( Bae, MK; Cha, J; Chang, H; Cho, BC; Chung, H; Hur, J; Kim, CB; Kim, DJ; Kim, HI; Kim, HR; Kim, JH; Lee, CG; Lee, CY; Lee, H; Lee, JG; Lee, SK; Lee, YC; Park, JC; Shin, SK, 2014) |
| "Adjuvant chemotherapy trial of TS-1 for gastric cancer study demonstrated that postoperative S-1 chemotherapy for 1 year improved overall survival of locally advanced gastric cancer (LAGC) patients." | 2.78 | A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH, 2013) |
| "4%) and renal adverse events (all grades: CS, 18." | 2.78 | Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013) |
| "How best to manage advanced esophageal cancer remains unresolved, especially in palliative care." | 2.73 | Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. ( Ahn, JS; Cho, SH; Chung, IJ; Kim, HJ; Kim, YK; Lee, JJ; Lee, SR; Nam, TK; Shim, HJ; Yang, DH, 2008) |
| "Chemoradiotherapy combined with 5-fluorouracil and cisplatin have been effective for the treatment of advanced esophageal cancer, but superior treatments are needed." | 2.72 | [Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer]. ( Iwase, H, 2006) |
| " We assumed that the recommended dosage of TXT was 30 mg/m(2) and that of TS-1 was 60 mg/m(2) with radiotherapy of 60 Gy." | 2.72 | [A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1]. ( Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2006) |
| "She had received 4 cycles of palliative therapy using oral apatinib (425 mg daily) plus S-1 (40 mg twice daily for 4 weeks, with a 2-week drug-free interval), followed by maintenance low-dose apatinib (250 mg daily) plus S-1 at the same dosage thereafter." | 2.66 | S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. ( Liu, D; Yu, GM; Zhang, C; Zhang, M, 2020) |
| " Thereafter, salvage minimally invasive Ivor-Lewis esophagectomy and 2-field lymph node dissection was performed, followed by oral apatinib plus S-1 at the prior dosage for 6 months." | 2.66 | S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature. ( Gong, LB; Wu, W; Yu, GM; Zhang, C; Zhang, M, 2020) |
| "Esophageal cancer is one of the worst malignant digestive neoplasms with poor treatment outcomes." | 2.58 | Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol. ( Liu, F; Song, Y; Wang, W; Xing, D, 2018) |
| "A 65-year-old woman ofesophageal cancer received preoperative chemotherapy, and developed EFR before operation." | 2.55 | [Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report]. ( Fujiwara, T; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Noma, K; Shirakawa, Y; Tanabe, S, 2017) |
| "In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer." | 2.52 | [Adjuvant treatment for esophagogastric junction cancer]. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
| " Dosing of S-1 is different between Western and Asian populations due to differences in metabolism by CYP2A6." | 2.44 | Medical treatment for advanced gastroesophageal adenocarcinoma. ( Ajani, JA; Cen, P, 2007) |
| " Patients were treated with apatinib combined with S-1 /capecitabine after dCRT." | 1.62 | Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy. ( Bai, K; Chen, B; Chi, D; Guo, S; Hu, Y; Li, Q; Ma, H; Zhu, Y, 2021) |
| " The main adverse events (AEs) of anlotinib combined with S-1 were fatigue (58." | 1.62 | Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy. ( Cai, J; Liu, A; Luo, Y; Zhou, S, 2021) |
| " Adverse events related to S-1 treatment were mostly grade 1 or 2 while reported grade 3-4 serious adverse events related to S-1 occurred in 12 patients and were most often grade 3 neutropenia (n = 4, 3." | 1.51 | S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study. ( Venerito, M, 2019) |
| "He was preoperatively diagnosed with esophageal cancer, T3N2M0, Stage III ." | 1.46 | [Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer]. ( Fujiwara, T; Kagawa, S; Komoto, S; Maeda, N; Matsumi, Y; Ninomiya, T; Nishizaki, M; Noma, K; Shirakawa, Y; Tanabe, S, 2017) |
| "Patients with early and advanced esophageal cancer and relapsed esophageal cancer after radical surgery were included." | 1.43 | Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer. ( Haga, A; Kiritoshi, T; Nakagawa, K; Ohtomo, K; Okuma, K; Takenaka, R; Yamashita, H, 2016) |
| "The patient died from recurrence of gastric cancer 69 months after completion of the initial chemotherapy and 2 months after the stent insertion." | 1.40 | [Effectiveness of chemoradiotherapy for a patient with local recurrence of advanced gastric cancer followed by curable gastrectomy]. ( Ishiyama, S; Iwasaki, Y; Maeda, Y; Natsume, S; Oohinata, R; Takahashi, K; Yajima, K; Yuu, K, 2014) |
| "Meanwhile, although funnel chest is generally a subclinical condition, patients with this deformity may sometimes present with cardiac failure and chest pain." | 1.39 | [A case of esophageal cancer with a funnel chest]. ( Akami, T; Matsumura, A; Matsuyama, T; Mugitani, T; Nishibeppu, K; Ogino, S; Shimode, Y; Takemura, M, 2013) |
| "It may be useful for esophageal squamous cell carcinoma (ESCC); however, there are insufficient data." | 1.39 | S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. ( Akutsu, Y; Hanaoka, T; Hoshino, I; Kono, T; Matsubara, H; Narushima, K; Qin, W; Semba, Y; Tochigi, T; Uesato, M, 2013) |
| "Advanced gastric cancer was found at the fundus of the stomach, and severe dysplasia was found at the lower esophagus." | 1.38 | [A case of advanced gastric cancer with esophageal severe dysplasia resected after neoadjuvant S-1+cisplatin therapy]. ( Hosaka, S; Inada, K; Kawamoto, S; Kikutake, T; Maeno, H; Nagao, S; Okubo, S; Umemoto, S; Yoshida, T, 2012) |
| "Patients with T4 esophageal cancer generally have poor prognosis." | 1.37 | [A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Yoneda, M, 2011) |
| "We report a case of early-stage mucosal esophageal cancer, showing a complete response to S-1 and cis-diamminedichloplatinum (CDDP)." | 1.37 | A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer. ( Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Mihara, Y; Miyazaki, T; Takayama, T; Takayama, Y; Tamegai, H; Watanabe, M, 2011) |
| "She was diagnosed as a type 3 gastric cancer (por/tub2) of the esophagogastric junction by gastrointestinal endoscopy in November 2010." | 1.37 | [A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy]. ( Ebisui, C; Ide, Y; Kinuta, M; Momozane, T; Mukai, R; Murakami, M; Murata, K; Nagase, H; Nishigaki, T; Okada, K; Owada, Y; Tamai, M; Yanagisawa, T; Yokouchi, H, 2011) |
| "Complications of esophageal cancer are particularly frequent in cases of hypopharyngeal cancer in comparison to other head and neck tumors." | 1.36 | [Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma]. ( Egawa, S; Furuya, A; Kobayashi, S; Mori, T; Ono, T; Sanbe, T; Shimane, T; Suzaki, H, 2010) |
| "Further examination showed esophageal cancer had metastasized to the cervical lymph nodes and invaded the trachea." | 1.35 | [Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers]. ( Hayashi, T; Hirano, N; Hoteya, S; Iizuka, T; Kikuchi, D; Mitani, T; Miyata, Y; Nakamura, M; Ochiai, Y; Sakurada, T; Yahagi, N, 2009) |
| "The diagnosis was the esophageal cancer (type 2, 11 cm) with big lymph node metastasis on cardia (8 cm), and also pathologically poorly differentiated squamous cell carcinoma from two legions." | 1.35 | [A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home]. ( Doi, T; Handa, R; Hoshi, M; Iijimal, S; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Ooshima, S, 2008) |
| "A 64-year-old woman with advanced esophageal cancer underwent chemotherapy with docetaxel/5-FU/CDDP (DFP)." | 1.35 | [Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy]. ( Honda, J; Matsuoka, H; Miyoshi, T; Seike, J; Tangoku, A; Yamai, H; Yoshida, T; Yuasa, Y, 2008) |
| "He was diagnosed as having esophageal cancer of stage IVa (T2N4M0) in October, 2002, and he received chemoradiotherapy (nedaplatin (CDGP)/5-fluorouracil (5-FU) total 6 course+60 Gy)." | 1.34 | [Recurrent esophageal cancer with complete response to TS-1 chemotherapy]. ( Chinen, T; Fujita, J; Hirata, T; Hokama, A; Kinjo, F; Kinjo, N; Nakachi, N; Nakamoto, M; Uchima, N; Watanabe, T, 2007) |
| "A 62-year-old woman with Barrett's esophageal cancer was hospitalized." | 1.34 | Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer. ( Azuma, M; Higuchi, K; Katada, C; Koizumi, W; Nakatani, K; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S, 2007) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 1.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "This chemotherapy made it possible to treat liver and lymph node metastasis in an ambulatory setting." | 1.33 | [A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination]. ( Hashimoto, Y; Hayashidani, Y; Morifuji, M; Murakami, Y; Sudo, A; Sueda, T; Sugiyama, Y; Uemura, K, 2006) |
| "We report a patient with advanced esophageal cancer who achieved a complete response to combination chemotherapy of TS-1, docetaxel and CDDP." | 1.33 | [Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer]. ( Kitakata, H; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K, 2006) |
| "Treatment of Barrett's esophageal cancer is often conducted in accordance with the principles of treatment of esophageal squamous cell carcinoma, and surgical resection represents the most effective treatment." | 1.32 | [A case of Barrett's esophageal cancer showing good response to combined chemotherapy with TS-1, CDDP and radiotherapy]. ( Fujiwara, Y; Fukuhara, K; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2003) |
| "A 70-year-old patient with advanced esophageal cancer with invasion to the aorta was treated by combined chemotherapy of TS-1 and CDDP with radiotherapy." | 1.32 | [Complete response in a case of advanced esophageal cancer treated by combined chemotherapy of TS-1 and CDDP with radiotherapy]. ( Doi, R; Indou, T; Iwase, H; Iyo, T; Kaida, S; Nakarai, K; Okeya, M; Shimada, M, 2004) |
| " After 7 days of treatment, grade 3 anorexia appeared, so the dosage of TS-1 was reduced to 25 mg/day." | 1.32 | [A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient]. ( Hasegawa, S; Hattori, H; Imazu, H; Komori, Y; Masui, T; Matsubara, T; Nagai, K; Nakamura, Y; Ochiai, M; Sakurai, Y; Syoji, M; Tonomura, S; Uyama, I; Yoshida, I, 2004) |
| "A 51-year-old male patient with esophageal cancer and cervical, thoracic and celiac artery lymph node metastases was treated by combination chemotherapy of TS-1 and cisplatin." | 1.32 | [A case of metastatic esophageal cancer responding remarkably to combination chemotherapy of TS-1 and cisplatin]. ( Doi, R; Iwase, H; Kaida, S; Nakarai, K; Okeya, M; Shimada, M; Tsuzuki, T, 2004) |
| "Gastrointestinal endoscopy showed esophageal cancer invading the gastric fundus." | 1.32 | Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin. ( Doi, R; Indo, T; Iwase, H; Kaida, S; Kato, E; Nakarai, K; Okeya, M; Shimada, M; Tsuzuki, T, 2004) |
| "A 66-year-old patient, who had advanced esophageal cancer with lymph node metastasis, was treated by neoadjuvant chemo-radiotherapy, followed by curative surgery." | 1.32 | [A case of advanced esophageal cancer responding remarkably to chemotherapy of TS-1 and weekly CDDP combined with radiotherapy]. ( Kabashima, A; Matsusaka, T; Nishizaki, T; Ojima, Y; Sakaguchi, Y; Shimabukuro, R; Tashiro, H; Yamamoto, H; Yamamura, S, 2004) |
| "Synchronous esophageal and gastric cancer were diagnosed by endoscopy and barium swallow." | 1.32 | [A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation]. ( Fujiwara, Y; Fukuhara, K; Harada, S; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2004) |
| " Beginning on August 9, 1999, TS-1 was administered in a dosage of 50 mg bid, but it was later learned that the patient had ingested only half of that TS-1 dosage (i." | 1.31 | [A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1]. ( Abe, S; Kitago, M; Kojima, M; Kurihara, H; Ogihara, T; Sasanuma, H; Tamura, H; Wada, M, 2002) |
| "Thus, gastric cancer was treated by chemotherapy and esophageal cancer by concurrent chemoradiotherapy with chemotherapy used for gastric cancer." | 1.31 | [Complete response in a case of simultaneous esophageal and gastric cancer treated by combined radiotherapy and chemotherapy of TS-1 and CDDP]. ( Hiraiwa, A; Indo, T; Iwase, H; Iyo, T; Kaida, S; Mizuno, T; Nakamura, M; Nakarai, K, 2002) |
| "The patient was a 78-year-old man." | 1.31 | [A case of gastric cancer in the stomach wall used for mediastinal reconstruction after esophagectomy in which surgery was abandoned due to advanced age and complications but TS-1 was useful]. ( Fujiwara, Y; Fukuhara, K; Hashimoto, Y; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Takada, N; Takemura, M; Tanaka, Y; Ueno, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (36.27) | 29.6817 |
| 2010's | 58 (56.86) | 24.3611 |
| 2020's | 7 (6.86) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J | 1 |
| Zhou, S | 1 |
| Luo, Y | 1 |
| Liu, A | 1 |
| Zhao, J | 1 |
| Lei, J | 1 |
| Yu, J | 1 |
| Zhang, C | 3 |
| Song, X | 1 |
| Zhang, N | 1 |
| Wang, Y | 2 |
| Zhang, S | 2 |
| Kudo, R | 1 |
| Manaka, D | 1 |
| Ikeda, Y | 1 |
| Ota, T | 1 |
| Hamasu, S | 1 |
| Konishi, S | 1 |
| Nishitai, R | 1 |
| Yu, GM | 2 |
| Zhang, M | 2 |
| Liu, D | 1 |
| Wu, W | 1 |
| Gong, LB | 1 |
| Kawazoe, A | 1 |
| Yamaguchi, K | 4 |
| Yasui, H | 1 |
| Negoro, Y | 1 |
| Azuma, M | 2 |
| Amagai, K | 1 |
| Hara, H | 1 |
| Baba, H | 1 |
| Tsuda, M | 1 |
| Hosaka, H | 1 |
| Kawakami, H | 1 |
| Oshima, T | 1 |
| Omuro, Y | 1 |
| Machida, N | 3 |
| Esaki, T | 1 |
| Yoshida, K | 4 |
| Nishina, T | 2 |
| Komatsu, Y | 1 |
| Han, SR | 1 |
| Shiratori, S | 1 |
| Shitara, K | 3 |
| Kanda, M | 1 |
| Koike, M | 1 |
| Iwata, N | 1 |
| Shimizu, D | 1 |
| Tanaka, C | 1 |
| Hattori, N | 1 |
| Hayashi, M | 1 |
| Yamada, S | 1 |
| Omae, K | 1 |
| Nakayama, G | 1 |
| Kodera, Y | 1 |
| Chi, D | 1 |
| Chen, B | 1 |
| Guo, S | 1 |
| Bai, K | 1 |
| Ma, H | 1 |
| Hu, Y | 1 |
| Li, Q | 1 |
| Zhu, Y | 1 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 1 |
| Lv, S | 1 |
| Li, J | 2 |
| Xu, H | 1 |
| Luo, L | 1 |
| Jia, Y | 2 |
| Song, GM | 1 |
| Tian, X | 1 |
| Liu, XL | 1 |
| Chen, H | 1 |
| Zhou, JG | 1 |
| Bian, W | 1 |
| Chen, WQ | 1 |
| Wang, F | 1 |
| Fan, QX | 1 |
| Wang, HH | 1 |
| Han, DM | 1 |
| Song, NS | 1 |
| Lu, H | 1 |
| Ter Veer, E | 2 |
| Ngai, LL | 2 |
| Valkenhoef, GV | 1 |
| Mohammad, NH | 1 |
| Anderegg, MCJ | 1 |
| van Oijen, MGH | 2 |
| van Laarhoven, HWM | 2 |
| Wen, Y | 1 |
| Zhao, Z | 1 |
| Miao, J | 1 |
| Yang, Q | 1 |
| Gui, Y | 1 |
| Sun, M | 1 |
| Tian, H | 1 |
| Jia, Q | 1 |
| Liao, D | 1 |
| Yang, C | 1 |
| Du, X | 1 |
| Komoto, S | 2 |
| Noma, K | 2 |
| Maeda, N | 2 |
| Matsumi, Y | 2 |
| Ninomiya, T | 2 |
| Tanabe, S | 3 |
| Shirakawa, Y | 2 |
| Fujiwara, T | 2 |
| Nishizaki, M | 1 |
| Kagawa, S | 1 |
| Wang, W | 2 |
| Xing, D | 1 |
| Song, Y | 1 |
| Liu, F | 1 |
| Kuroda, J | 1 |
| Aoki, H | 2 |
| Kondou, N | 1 |
| Sumita, T | 1 |
| Itoh, K | 1 |
| Agawa, S | 1 |
| Ojima, T | 1 |
| Nakamura, M | 5 |
| Nakamori, M | 1 |
| Katsuda, M | 1 |
| Hayata, K | 1 |
| Maruoka, S | 1 |
| Shimokawa, T | 1 |
| Yamaue, H | 1 |
| Sun, S | 1 |
| Yu, H | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Wu, X | 1 |
| Wang, J | 2 |
| Chang, J | 1 |
| Venerito, M | 1 |
| Huang, J | 2 |
| Xu, B | 1 |
| Liu, Y | 1 |
| Lu, P | 1 |
| Ba, Y | 1 |
| Wu, L | 1 |
| Bai, Y | 1 |
| Feng, J | 1 |
| Cheng, Y | 2 |
| Wen, L | 1 |
| Yuan, X | 1 |
| Ma, C | 1 |
| Hu, C | 1 |
| Fan, Q | 1 |
| Wang, X | 3 |
| Li, C | 1 |
| Han, C | 1 |
| Wang, P | 1 |
| Pang, Q | 1 |
| Chen, J | 1 |
| Sun, X | 1 |
| Wang, L | 1 |
| Zhang, W | 1 |
| Lin, Y | 1 |
| Ge, X | 1 |
| Zhou, Z | 1 |
| Ni, W | 1 |
| Chang, X | 1 |
| Liang, J | 1 |
| Deng, L | 1 |
| Zhao, Y | 2 |
| Xiao, Z | 1 |
| Liu, X | 1 |
| Jin, J | 1 |
| Cai, H | 1 |
| Huang, H | 1 |
| Zhao, G | 1 |
| Zhou, Y | 1 |
| Wu, J | 1 |
| Du, C | 1 |
| Long, Z | 1 |
| Fang, Y | 1 |
| Ma, M | 1 |
| Li, G | 1 |
| Zhou, M | 1 |
| Yin, J | 1 |
| Zhu, X | 1 |
| Zhu, J | 1 |
| Sheng, W | 1 |
| Huang, D | 1 |
| Zhu, H | 1 |
| Zhang, Z | 3 |
| Lu, Q | 1 |
| Xie, L | 1 |
| Ito, T | 2 |
| Honma, Y | 1 |
| Hirano, H | 1 |
| Shoji, H | 1 |
| Okita, N | 1 |
| Iwasa, S | 1 |
| Takashima, A | 1 |
| Kato, K | 2 |
| Boku, N | 3 |
| Kobayashi, R | 1 |
| Yamashita, H | 2 |
| Okuma, K | 2 |
| Shiraishi, K | 1 |
| Ohtomo, K | 2 |
| Nakagawa, K | 2 |
| Akutsu, Y | 1 |
| Kono, T | 1 |
| Uesato, M | 1 |
| Hoshino, I | 1 |
| Narushima, K | 1 |
| Hanaoka, T | 1 |
| Tochigi, T | 1 |
| Semba, Y | 1 |
| Qin, W | 1 |
| Matsubara, H | 1 |
| Iwase, H | 7 |
| Shimada, M | 5 |
| Tsuzuki, T | 3 |
| Hirashima, N | 1 |
| Okeya, M | 5 |
| Hibino, Y | 1 |
| Ryuge, N | 1 |
| Yokoi, M | 1 |
| Kida, Y | 1 |
| Kuno, T | 1 |
| Tanaka, Y | 6 |
| Kato, B | 1 |
| Esaki, M | 1 |
| Urata, N | 1 |
| Kato, E | 3 |
| Ajani, JA | 4 |
| Buyse, M | 1 |
| Lichinitser, M | 2 |
| Gorbunova, V | 2 |
| Bodoky, G | 3 |
| Douillard, JY | 1 |
| Cascinu, S | 2 |
| Heinemann, V | 1 |
| Zaucha, R | 1 |
| Carrato, A | 2 |
| Ferry, D | 1 |
| Moiseyenko, V | 3 |
| Park, I | 1 |
| Ryu, MH | 1 |
| Choi, YH | 1 |
| Kang, HJ | 1 |
| Yook, JH | 1 |
| Park, YS | 1 |
| Kim, HJ | 2 |
| Jung, HY | 2 |
| Lee, GH | 2 |
| Kim, KC | 1 |
| Kim, BS | 1 |
| Kang, YK | 1 |
| Takemura, M | 4 |
| Matsuyama, T | 1 |
| Nishibeppu, K | 1 |
| Matsumura, A | 1 |
| Ogino, S | 1 |
| Mugitani, T | 1 |
| Akami, T | 1 |
| Shimode, Y | 1 |
| Chang, H | 1 |
| Shin, SK | 1 |
| Cho, BC | 1 |
| Lee, CG | 1 |
| Kim, CB | 1 |
| Kim, DJ | 1 |
| Lee, JG | 1 |
| Hur, J | 1 |
| Lee, CY | 1 |
| Bae, MK | 1 |
| Kim, HR | 2 |
| Lee, SK | 1 |
| Park, JC | 1 |
| Lee, H | 1 |
| Kim, HI | 1 |
| Chung, H | 1 |
| Cha, J | 1 |
| Lee, YC | 1 |
| Kim, JH | 2 |
| Matsumoto, H | 4 |
| Kubota, H | 3 |
| Higashida, M | 4 |
| Yoden, E | 2 |
| Hiratsuka, J | 3 |
| Haruma, K | 1 |
| Hirai, T | 5 |
| Yoon, DH | 1 |
| Jang, G | 1 |
| Kim, YH | 1 |
| Kim, JY | 1 |
| Song, HY | 1 |
| Cho, KJ | 1 |
| Ryu, JS | 1 |
| Kim, SB | 1 |
| Fuse, N | 2 |
| Kuboki, Y | 1 |
| Kuwata, T | 1 |
| Kadowaki, S | 1 |
| Shinozaki, E | 1 |
| Yuki, S | 1 |
| Ooki, A | 1 |
| Kajiura, S | 1 |
| Kimura, T | 1 |
| Yamanaka, T | 1 |
| Nagatsuma, AK | 1 |
| Yoshino, T | 1 |
| Ochiai, A | 1 |
| Ohtsu, A | 2 |
| Scheulen, ME | 1 |
| Rivera, F | 1 |
| Jassem, J | 1 |
| Vynnychenko, I | 2 |
| Prausová, J | 1 |
| Van Laethem, JL | 1 |
| Natsume, S | 1 |
| Iwasaki, Y | 1 |
| Yajima, K | 1 |
| Yuu, K | 1 |
| Oohinata, R | 1 |
| Ishiyama, S | 1 |
| Takahashi, K | 1 |
| Maeda, Y | 1 |
| Nagai, Y | 1 |
| Kato, T | 3 |
| Harano, M | 1 |
| Satoh, D | 1 |
| Choda, Y | 1 |
| Tokumoto, N | 1 |
| Kanazawa, T | 1 |
| Matsukawa, H | 1 |
| Ojima, Y | 2 |
| Idani, H | 1 |
| Shiozaki, S | 1 |
| Okajima, M | 1 |
| Ninomiya, M | 1 |
| Ohno, S | 1 |
| Kurokawa, Y | 1 |
| Takiguchi, S | 1 |
| Miyazaki, Y | 1 |
| Takahashi, T | 3 |
| Yamasaki, M | 1 |
| Miyata, H | 1 |
| Nakajima, K | 1 |
| Mori, M | 1 |
| Doki, Y | 1 |
| Tahara, M | 1 |
| Mizusawa, J | 2 |
| Sato, A | 1 |
| Nihei, K | 1 |
| Kanato, K | 1 |
| Yamazaki, K | 1 |
| Muro, K | 1 |
| Takaishi, H | 1 |
| Kataoka, K | 1 |
| Tokunaga, M | 1 |
| Katayama, H | 1 |
| Tomita, T | 1 |
| Nakamura, K | 2 |
| Sano, T | 1 |
| Terashima, M | 2 |
| Sasako, M | 1 |
| Haga, A | 1 |
| Takenaka, R | 1 |
| Kiritoshi, T | 1 |
| Nakao, E | 1 |
| Iijima, S | 1 |
| Tsujimura, N | 1 |
| Matsumoto, T | 1 |
| Takemoto, H | 1 |
| Takachi, K | 1 |
| Nishioka, K | 1 |
| Oshima, S | 1 |
| Uemura, Y | 1 |
| Yao, B | 1 |
| Tan, B | 1 |
| Wang, C | 1 |
| Song, Q | 1 |
| Guan, S | 1 |
| Ma, Y | 1 |
| Huang, X | 1 |
| Sun, Y | 1 |
| Tanahashi, T | 1 |
| Okumura, N | 1 |
| Matsuhashi, N | 1 |
| Haj Mohammad, N | 1 |
| van Valkenhoef, G | 1 |
| Mali, RMA | 1 |
| Anderegg, MC | 1 |
| Kano, K | 1 |
| Sato, T | 2 |
| Maezawa, Y | 1 |
| Segami, K | 1 |
| Nakajima, T | 1 |
| Ikeda, K | 1 |
| Hayashi, T | 2 |
| Yamada, T | 2 |
| Yamamoto, N | 1 |
| Ohshima, T | 1 |
| Yukawa, N | 1 |
| Rino, Y | 1 |
| Masuda, M | 1 |
| Ogata, T | 1 |
| Cho, H | 1 |
| Yoshikawa, T | 1 |
| Wang, HY | 1 |
| Yao, ZH | 1 |
| Tang, H | 1 |
| Jin, SL | 1 |
| Zhou, WP | 1 |
| Yao, SN | 1 |
| Yang, SJ | 1 |
| Liu, YY | 1 |
| Luo, SX | 1 |
| Nie, K | 1 |
| Geng, C | 1 |
| Zhang, L | 1 |
| Liu, S | 1 |
| Wang, R | 1 |
| Zou, X | 1 |
| Ji, Y | 1 |
| Murakami, K | 1 |
| Tamura, S | 1 |
| Takeno, A | 1 |
| Ishida, T | 1 |
| Kuwahara, R | 1 |
| Akiyama, Y | 1 |
| Sakamoto, T | 1 |
| Inatome, J | 1 |
| Naito, A | 1 |
| Katsura, Y | 1 |
| Ohmura, Y | 1 |
| Kagawa, Y | 1 |
| Egawa, C | 1 |
| Takeda, Y | 1 |
| Cho, SH | 1 |
| Shim, HJ | 1 |
| Lee, SR | 1 |
| Ahn, JS | 1 |
| Yang, DH | 1 |
| Kim, YK | 1 |
| Nam, TK | 1 |
| Lee, JJ | 1 |
| Chung, IJ | 1 |
| Kojima, T | 1 |
| Matsui, T | 1 |
| Uemura, T | 1 |
| Fujimitsu, Y | 1 |
| Kure, N | 1 |
| Mochizuki, Y | 2 |
| Kojima, H | 1 |
| Sugawara, H | 1 |
| Ichiki, M | 1 |
| Sai, K | 1 |
| Kamata, K | 1 |
| Ansai, M | 1 |
| Nakano, Y | 1 |
| Kawamura, M | 1 |
| Ichinose, A | 1 |
| Miyazaki, S | 1 |
| Kikuchi, D | 1 |
| Iizuka, T | 1 |
| Hoteya, S | 1 |
| Miyata, Y | 1 |
| Mitani, T | 1 |
| Ochiai, Y | 1 |
| Sakurada, T | 1 |
| Hirano, N | 1 |
| Yahagi, N | 1 |
| Saito, A | 1 |
| Kaida, Y | 1 |
| Murakami, H | 3 |
| Hirabayashi, Y | 2 |
| Oka, Y | 2 |
| Okumura, H | 2 |
| Uragami, A | 1 |
| Yamashita, K | 3 |
| Ohyama, M | 1 |
| Ikeda, H | 1 |
| Okabe, M | 1 |
| Morimoto, Y | 1 |
| Kawamoto, K | 1 |
| Sano, K | 1 |
| Paku, T | 1 |
| Imai, S | 1 |
| Yoshida, Y | 1 |
| Ogasahara, K | 1 |
| Rodriguez, W | 1 |
| Garin, A | 1 |
| Lang, I | 1 |
| Falcon, S | 1 |
| Hiraki, M | 2 |
| Tanaka, M | 1 |
| Sato, S | 1 |
| Kai, K | 1 |
| Morito, K | 1 |
| Kobayashi, K | 1 |
| Noshiro, H | 1 |
| Tokunaga, O | 1 |
| Miyazaki, K | 1 |
| Iijimal, S | 1 |
| Makari, Y | 1 |
| Handa, R | 1 |
| Ooshima, S | 1 |
| Miyake, Y | 1 |
| Hoshi, M | 1 |
| Doi, T | 1 |
| Kurokawa, E | 1 |
| Kikkawa, N | 1 |
| Matsuda, S | 1 |
| Takahashi, M | 1 |
| Watanabe, J | 1 |
| Yabuno, T | 1 |
| Kito, F | 1 |
| Kunisaki, C | 1 |
| Shimane, T | 1 |
| Mori, T | 1 |
| Ono, T | 1 |
| Egawa, S | 1 |
| Furuya, A | 1 |
| Kobayashi, S | 1 |
| Sanbe, T | 1 |
| Suzaki, H | 1 |
| Shinoto, M | 1 |
| Shioyama, Y | 1 |
| Sasaki, T | 2 |
| Ohura, H | 1 |
| Toh, Y | 1 |
| Higaki, Y | 1 |
| Yamaguchi, T | 1 |
| Ohnishi, K | 1 |
| Atsumi, K | 1 |
| Hirata, H | 1 |
| Honda, H | 1 |
| Takayama, Y | 1 |
| Kochi, M | 3 |
| Fujii, M | 4 |
| Kanamori, N | 3 |
| Kaiga, T | 2 |
| Mihara, Y | 2 |
| Miyazaki, T | 2 |
| Tamegai, H | 1 |
| Watanabe, M | 1 |
| Takayama, T | 4 |
| Fujiwara, H | 2 |
| Koeda, K | 1 |
| Konosu, M | 1 |
| Hosoi, N | 1 |
| Tamasawa, Y | 1 |
| Sase, M | 1 |
| Tsukahara, T | 1 |
| Ushio, A | 1 |
| Taguchi, M | 1 |
| Wakabayashi, G | 1 |
| Osada, S | 1 |
| Ebisui, C | 1 |
| Okada, K | 1 |
| Nishigaki, T | 1 |
| Owada, Y | 1 |
| Nagase, H | 1 |
| Mukai, R | 1 |
| Momozane, T | 1 |
| Murakami, M | 1 |
| Ide, Y | 1 |
| Yanagisawa, T | 1 |
| Murata, K | 1 |
| Yokouchi, H | 1 |
| Tamai, M | 1 |
| Kinuta, M | 1 |
| Yoneda, M | 1 |
| Shiozaki, A | 1 |
| Komatsu, S | 1 |
| Ichikawa, D | 1 |
| Okamoto, K | 1 |
| Murayama, Y | 1 |
| Kuriu, Y | 1 |
| Ikoma, H | 1 |
| Nakanishi, M | 1 |
| Ochiai, T | 1 |
| Kokuba, Y | 1 |
| Otsuji, E | 1 |
| Nakamura, T | 1 |
| Ota, M | 1 |
| Narumiya, K | 1 |
| Shirai, Y | 1 |
| Yamamoto, M | 1 |
| Kuramochi, H | 1 |
| Hayashi, K | 2 |
| Nakajima, Y | 1 |
| Fujiwara, N | 1 |
| Ryotokuji, T | 1 |
| Ohta, S | 1 |
| Okada, T | 1 |
| Miyawaki, Y | 1 |
| Hoshino, A | 1 |
| Jirawat, S | 1 |
| Tokairin, Y | 1 |
| Kawada, K | 1 |
| Nishikage, T | 1 |
| Nagai, K | 2 |
| Kawano, T | 1 |
| Matsuno, Y | 1 |
| Funada, T | 1 |
| Kawabe, Y | 2 |
| Nakashima, H | 1 |
| Umemoto, S | 1 |
| Hosaka, S | 1 |
| Kikutake, T | 1 |
| Okubo, S | 1 |
| Maeno, H | 1 |
| Inada, K | 1 |
| Nagao, S | 1 |
| Kawamoto, S | 1 |
| Yoshida, T | 3 |
| Abe, S | 1 |
| Kojima, M | 1 |
| Kurihara, H | 1 |
| Tamura, H | 1 |
| Kitago, M | 1 |
| Sasanuma, H | 1 |
| Wada, M | 1 |
| Ogihara, T | 1 |
| Osugi, H | 3 |
| Lee, S | 3 |
| Taguchi, S | 2 |
| Kaneko, M | 2 |
| Fukuhara, K | 3 |
| Fujiwara, Y | 3 |
| Nishizawa, S | 3 |
| Kinoshita, H | 3 |
| Wakabayashi, K | 2 |
| Hayashi, S | 1 |
| Masuda, H | 1 |
| Karube, H | 1 |
| Ookame, H | 1 |
| Sakamoto, N | 1 |
| Tanaka, A | 1 |
| Funai, S | 1 |
| Ohtsuka, H | 1 |
| Yoshifuji, T | 1 |
| Shindo, K | 1 |
| Shiozaki, H | 1 |
| Kamei, A | 1 |
| Nakarai, K | 5 |
| Iyo, T | 2 |
| Kaida, S | 5 |
| Indou, T | 1 |
| Doi, R | 4 |
| Harada, S | 1 |
| Imazu, H | 1 |
| Ochiai, M | 1 |
| Sakurai, Y | 1 |
| Komori, Y | 1 |
| Uyama, I | 1 |
| Matsubara, T | 1 |
| Hasegawa, S | 1 |
| Nakamura, Y | 1 |
| Syoji, M | 1 |
| Yoshida, I | 1 |
| Masui, T | 1 |
| Tonomura, S | 1 |
| Hattori, H | 1 |
| Indo, T | 3 |
| Tuzuki, T | 1 |
| Sakaguchi, Y | 1 |
| Kabashima, A | 1 |
| Yamamoto, H | 1 |
| Shimabukuro, R | 1 |
| Yamamura, S | 1 |
| Nishizaki, T | 1 |
| Tashiro, H | 1 |
| Matsusaka, T | 1 |
| Inaba, H | 1 |
| Miyazaki, A | 1 |
| Tsuda, T | 1 |
| Akasaka, H | 1 |
| Kobayashi, M | 1 |
| Okamoto, M | 1 |
| Ogihara, K | 1 |
| Yamauchi, S | 1 |
| Koro, T | 1 |
| Katoh, N | 1 |
| Fujita, K | 1 |
| Watanabe, Y | 1 |
| Abiko, R | 1 |
| Nakaya, S | 1 |
| Kitajima, S | 1 |
| Hoshikawa, Y | 1 |
| Kimura, M | 1 |
| Itoh, F | 1 |
| Yunotani, S | 1 |
| Noguchi, R | 1 |
| Shinozaki, Y | 1 |
| Tani, H | 1 |
| Sakai, M | 1 |
| Ishimitsu, T | 1 |
| Tabuchi, M | 1 |
| Masuda, A | 1 |
| Tongu, M | 1 |
| Hiraku, O | 1 |
| Etou, T | 1 |
| Sasaki, K | 1 |
| Atsuda, K | 1 |
| Morinaga, S | 1 |
| Suzuki, T | 1 |
| Suzuki, Y | 1 |
| Osaku, M | 1 |
| Miyagawa, T | 1 |
| Asanuma, F | 1 |
| Yamada, Y | 1 |
| Sugiyama, Y | 1 |
| Morifuji, M | 1 |
| Murakami, Y | 1 |
| Uemura, K | 1 |
| Hayashidani, Y | 1 |
| Sudo, A | 1 |
| Hashimoto, Y | 2 |
| Sueda, T | 1 |
| Yasumoto, K | 1 |
| Kitakata, H | 1 |
| Omote, K | 1 |
| Takahashi, Y | 1 |
| Seike, J | 2 |
| Honda, J | 2 |
| Miyoshi, T | 2 |
| Umemoto, A | 1 |
| Tangoku, A | 2 |
| Urakami, A | 1 |
| Imajyo, Y | 1 |
| Tsunoda, T | 1 |
| Yasumura, T | 1 |
| Maruyama, T | 1 |
| Kaji, S | 1 |
| Yagawa, A | 1 |
| Ozawa, T | 1 |
| Watanabe, T | 1 |
| Chinen, T | 1 |
| Nakachi, N | 1 |
| Nakamoto, M | 1 |
| Uchima, N | 1 |
| Hirata, T | 1 |
| Hokama, A | 1 |
| Kinjo, N | 1 |
| Kinjo, F | 1 |
| Fujita, J | 1 |
| Nakatani, K | 1 |
| Koizumi, W | 1 |
| Nishimura, K | 1 |
| Shimoda, T | 1 |
| Katada, C | 1 |
| Higuchi, K | 1 |
| Saigenji, K | 1 |
| Sou, K | 1 |
| Cen, P | 1 |
| Tokuhara, T | 1 |
| Okuda, T | 1 |
| Sakata, C | 1 |
| Nishikawa, M | 1 |
| Morita, R | 1 |
| Motoyama, S | 1 |
| Mori, K | 1 |
| Maruyama, K | 1 |
| Sato, Y | 1 |
| Usami, S | 1 |
| Suzuki, H | 1 |
| Ogawa, J | 1 |
| Takada, J | 1 |
| Okuda, K | 1 |
| Tani, C | 1 |
| Kenno, S | 1 |
| Oguro, S | 1 |
| Shimokuni, T | 1 |
| Aoki, T | 1 |
| Nagaoka, Y | 1 |
| Uno, Y | 1 |
| Hamada, H | 1 |
| Matsuoka, H | 1 |
| Yuasa, Y | 1 |
| Yamai, H | 1 |
| Shirasaka, T | 1 |
| Yamamitsu, S | 1 |
| Tsuji, A | 1 |
| Hirata, K | 1 |
| Mizuno, T | 1 |
| Hiraiwa, A | 1 |
| Takada, N | 1 |
| Ueno, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| A Phase IIb, Clinical Trial to Study the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in Participants With Advanced or Recurrent Gastric Cancer (KEYNOTE-659)[NCT03382600] | Phase 2 | 100 participants (Actual) | Interventional | 2018-03-26 | Completed | ||
| Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study[NCT02319187] | Phase 3 | 240 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)[NCT02979691] | Phase 2/Phase 3 | 350 participants (Anticipated) | Interventional | 2016-10-31 | Completed | ||
| A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma (PREACT Study)[NCT03013010] | Phase 3 | 682 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma[NCT05161572] | Phase 2 | 152 participants (Anticipated) | Interventional | 2021-09-28 | Recruiting | ||
| Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma[NCT02325986] | Phase 2 | 46 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842] | Phase 2 | 0 participants (Actual) | Interventional | 2017-10-30 | Withdrawn (stopped due to non-accrual) | ||
| Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096] | Phase 2 | 35 participants (Anticipated) | Interventional | 2017-02-01 | Recruiting | ||
| Toripalimab Combined With Docetaxel or Nab-paclitaxel in the Treatment of Advanced Gastric Cancer : a Single-arm, Open Label, Prospective Phase II Clinical Trial[NCT04563975] | Phase 2 | 54 participants (Anticipated) | Interventional | 2020-07-02 | Recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DCR was defined as the percentage of participants in the analysis population who have CR (disappearance of all target lesions), PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD), or stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD [≥20% increase in the SOD of target lesions]). Responses are according to iRECIST 1.1 as assessed by BICR. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 96.3 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 97.8 |
DCR was defined as the percentage of participants in the analysis population who have complete response (CR, disappearance of all target lesions), partial response (PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD), or stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD, ≥20% increase in the SOD of target lesions]). Responses are according to RECIST 1.1 as assessed by BICR. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 96.3 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 97.8 |
For participants who demonstrated complete response (CR, disappearance of all target lesions) or partial response (PR, ≥30% decrease in the SOD of target lesions) according to iRECIST as assessed by BICR, DOR was defined as the time from the earliest date of qualifying response (CR or PR) until earliest date of progressive disease (PD, ≥20% increase in the SOD of target lesions) or death from any cause, whichever came first. DOR was censored at the last tumor assessment date if a responder did not have PD or death. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 10.6 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 9.5 |
For participants who demonstrated complete response (CR, disappearance of all target lesions) or partial response (PR, ≥30% decrease in the SOD of target lesions) according to RECIST 1.1 as assessed by BICR, DOR was defined as the time from the earliest date of qualifying response (CR or PR) until earliest date of progressive disease (PD, ≥20% increase in the SOD of target lesions) or death from any cause, whichever came first. DOR was censored at the last tumor assessment date if a responder did not have PD or death. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 10.6 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 9.5 |
An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 3 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 3 |
An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 54 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 46 |
For the primary efficacy analysis, ORR was defined as the percentage of participants who have a best response of complete response (CR, disappearance of all target lesions) or partial response (PR, at least a 30% decrease in the sum of diameters [SOD] of target lesions, taking as reference the baseline SOD) per RECIST 1.1 as assessed by BICR. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 72.2 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 80.4 |
For the secondary efficacy analysis, ORR was defined as the percentage of participants whose best response based on imaging is CR (disappearance of all target lesions) or PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD) according to iRECIST as assessed by BICR. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 72.2 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 80.4 |
OS was defined as the time from the date of enrollment day to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. For these participants, date of last follow up was last visit date instead of death date. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 16.9 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 17.1 |
PFS was defined as the time from the date of enrollment day to the first documented PD (defined as ≥20% increase in the SOD of target lesions) or death due to any cause, whichever occurred first. Responses are according to iRECIST 1.1 as assessed by BICR. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 9.4 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 10.9 |
PFS was defined as the time from the date of enrollment day to the first documented PD (defined as ≥20% increase in the SOD of target lesions) or death due to any cause, whichever occurred first. Responses are according to RECIST 1.1 as assessed by BICR. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 9.4 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 8.3 |
TTR was defined as the time from the date of enrollment day to the first date of confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD). Responses are according to RECIST 1.1 as assessed by BICR. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 1.5 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 1.5 |
TTR was defined as the time from the date of enrollment day to the first date of confirmed CR (disappearance of all target lesions) or PR (≥30% decrease in the SOD of target lesions, taking as reference the baseline SOD). Responses are according to iRECIST 1.1 as assessed by BICR. iRECIST is a modification to RECIST that takes into account unique patterns of atypical response in immunotherapy and enables treatment beyond initial radiographic progression. (NCT03382600)
Timeframe: Up to ~36 months
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1) | 1.5 |
| Pembrolizumab + Cisplatin +TS-1 (Cohort 2) | 1.5 |
Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 6.5 |
| 5-FU/Cisplatin | 5.8 |
Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 8.6 |
| 5-FU/Cisplatin | 7.9 |
The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).
| Intervention | Percentage of patients in each group (Number) |
|---|---|
| S-1/Cisplatin | 29.1 |
| 5-FU/Cisplatin | 31.9 |
The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 4.8 |
| 5-FU/Cisplatin | 5.5 |
The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
| Intervention | Months (Median) |
|---|---|
| S-1/Cisplatin | 3.8 |
| 5-FU/Cisplatin | 3.8 |
12 reviews available for oxonic acid and Cancer of Esophagus
| Article | Year |
|---|---|
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junc | 2020 |
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Combinations; Drug Resistance, Neoplasm | 2020 |
Concurrent chemo-radiotherapy with S-1 as an alternative therapy for elderly Chinese patients with non-metastatic esophageal squamous cancer: evidence based on a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Dru | 2017 |
Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2017 |
[Successful Multimodality Treatment Including Three-Stage Operation for Esophageal Cancer with Esophagorespiratory Fistula - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Drug | 2017 |
Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; Humans; | 2018 |
[Adjuvant treatment for esophagogastric junction cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Capecitabine; Carboplatin; Chemoradiotherapy, | 2015 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin | 2016 |
[Recurrence of esophageal cancer treated by combination TS-1/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Admini | 2005 |
[A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
Medical treatment for advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2007 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
26 trials available for oxonic acid and Cancer of Esophagus
| Article | Year |
|---|---|
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esop | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
S-1 versus S-1 plus cisplatin concurrent intensity modulated radiation therapy in the treatment of esophageal squamous cell carcinoma: Study protocol for a randomized controlled phase II trial.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Combinations; | 2017 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2018 |
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2019 |
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2019 |
Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2013 |
A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Sur | 2014 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Es | 2014 |
Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2015 |
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2015 |
A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JC
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2015 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Com | 2016 |
Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Drug Combinations; | 2008 |
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Res | 2011 |
[Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
64 other studies available for oxonic acid and Cancer of Esophagus
| Article | Year |
|---|---|
Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Humans; Indoles; Neoplasm | 2021 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dr | 2019 |
Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2021 |
[Radical Thoracoscopic Esophagectomy for Elderly Patients with Advanced Esophageal Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther | 2017 |
[A Case of Advanced Esophagogastric Junction Cancer Responding to S-1 Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Esophagoga | 2018 |
S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
[A case of esophageal cancer with a funnel chest].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Esophageal Neoplasms; E | 2013 |
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; | 2016 |
[Effectiveness of chemoradiotherapy for a patient with local recurrence of advanced gastric cancer followed by curable gastrectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Drug Combinations; Eso | 2014 |
[A case of AFP-producing esophagogastric junction cancer with liver metastases with a good response to chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Es | 2014 |
Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Car | 2016 |
[A Case of Carcinosarcoma of the Esophagus Treated with Chemoradiotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinosarcoma; Chemoradiotherapy; Drug Combinat | 2015 |
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2016 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2016 |
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cispla | 2017 |
Clinical Observation of Bevacizumab Combined with S-1 in the Treatment of Pretreated Advanced Esophageal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Combinations; Esophag | 2016 |
[A Case of Successful Multidisciplinary Therapy for Advanced Esophagogastric Junction Cancer with Multiple Lymph Node Metastase].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Esoph | 2016 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo | 2008 |
[Noticeable clinical response to S-1/CDDP combination therapy for Virchow node recurrence after surgery for advanced gastric carcinoma with marked involvement of the esophagus - report of a case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combination | 2009 |
[Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Electrocardiogr | 2009 |
[A case of chemo-radiation therapy with high degree of efficacy for esophageal cancer with liver metastasis].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
[Complete response in a case of advanced unresectable esophageal cancer treated by chemoradiation therapy and S-1+CDDP chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Combined | 2010 |
A complete response in small cell carcinoma of the esophagus treated by s-1/cisplatin combined chemotherapy and radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthma; Carcinoma, Small Cell; Cisplatin; Comb | 2010 |
[A 14-month surviving patient on advanced esophageal cancer with big lymph node metastasis to cardia responding to S-1 plus cisplatin (CDDP) therapy at home].
Topics: Aged; Antineoplastic Agents; Cardia; Cisplatin; Drug Combinations; Esophageal Neoplasms; Esophagosco | 2008 |
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; | 2010 |
[Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; | 2010 |
Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, S | 2011 |
A case of complete response to S-1 plus CDDP in early-stage mucosal esophageal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combina | 2011 |
[A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T | 2011 |
[A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2011 |
[A case of residual metastatic lymph node lesion following definitive chemoradiotherapy for T4 esophageal cancer, successfully treated by outpatient clinic-based sequential chemotherapy with docetaxel followed by S-1].
Topics: Aged; Ambulatory Care Facilities; Antineoplastic Agents; Chemoradiotherapy; Docetaxel; Drug Combinat | 2011 |
[Docetaxel plus S-1 as a second-line chemotherapy for metastasis or recurrence of esophageal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophagea | 2012 |
A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |
A complete response to S-1 plus cis-diamminedichloroplatinum in advanced-stage esophageal and gastric adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cisplatin; Disease Progression; Drug Combinat | 2012 |
Evaluation of 5-FU plasma concentration by 13C breath test in patients treated with oral 5-FU analogs.
Topics: Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes | 2012 |
[A case of advanced gastric cancer with esophageal severe dysplasia resected after neoadjuvant S-1+cisplatin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2012 |
[A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Gastrectom | 2002 |
[A case of Barrett's esophageal cancer showing good response to combined chemotherapy with TS-1, CDDP and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Combined Modalit | 2003 |
[Remarkable response of simultaneous advanced esophageal and gastric cancer to combined chemotherapy with weekday-on/Weekend-off TS-1 plus biweekly cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Carcinoma, Squamo | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration S | 2003 |
[Complete response in a case of advanced esophageal cancer treated by combined chemotherapy of TS-1 and CDDP with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
[A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2004 |
[A case of Barrett's esophageal carcinoma successfully treated with TS-1 in an elderly patient].
Topics: Aged; Antimetabolites, Antineoplastic; Barrett Esophagus; Drug Administration Schedule; Drug Combina | 2004 |
[A case of metastatic esophageal cancer responding remarkably to combination chemotherapy of TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administra | 2004 |
[A case of advanced cervical and upper thoracic esophageal carcinoma completely responding to chemoradiotherapy with TS-1 and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2004 |
Esophageal cancer with colonic metastasis successfully treated by chemoradiotherapy followed by chemotherapy with S-1 and cisplatin.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
[A case of advanced esophageal cancer responding remarkably to chemotherapy of TS-1 and weekly CDDP combined with radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2004 |
[Pilot study of concomitant TS-1/CDGP radiotherapy for esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 2005 |
[Experimental chemotherapy against human esophageal carcinoma xenografts with TS-1, cisplatin and docetaxel].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Dr | 2006 |
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2006 |
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
[Complete response in a case of advanced esophageal and gastric double cancer treated by chemotherapy of TS-1 and low-dose cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2006 |
[Recurrent esophageal cancer with complete response to TS-1 chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Ther | 2007 |
Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; Drug C | 2007 |
[Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2007 |
[S-1 chemotherapy for cancer of the gastric tube used for esophageal reconstruction following surgery for esophageal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Drug Combinations; Esophage | 2007 |
[Complete recovery obtained with combined S-1 + CDDP therapy in a patient with multiple lung metastases from esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Esophageal Neopl | 2007 |
[Complete response in a case of advanced esophageal cancer treated with docetaxel/5-FU/CDDPand S-1/docetaxel as neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Esophageal | 2008 |
[Complete response in a case of simultaneous esophageal and gastric cancer treated by combined radiotherapy and chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 2002 |
[A case of gastric cancer in the stomach wall used for mediastinal reconstruction after esophagectomy in which surgery was abandoned due to advanced age and complications but TS-1 was useful].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug | 2002 |